NasdaqGS:NXTM

Stock Analysis Report

Executive Summary

NxStage Medical, Inc., a medical technology company, develops, manufactures and markets products for the treatment of end-stage renal disease (ESRD) and acute kidney failure.

Snowflake

Fundamentals

Excellent balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has Nxstage Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.4%

NXTM

-0.4%

US Medical Equipment

1.0%

US Market


1 Year Return

27.7%

NXTM

12.8%

US Medical Equipment

6.7%

US Market


Share holder returns

NXTMIndustryMarket
7 Day2.4%-0.4%1.0%
30 Day5.5%-2.7%-1.8%
90 Day3.2%-0.3%-1.8%
1 Year27.7%27.7%13.7%12.8%9.1%6.7%
3 Year97.8%97.8%70.0%64.8%46.1%36.6%
5 Year116.3%116.3%130.9%105.1%66.9%48.6%

Price Volatility Vs. Market

How volatile is Nxstage Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Nxstage Medical undervalued based on future cash flows and its price relative to the stock market?

8.88x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Information is not available.

Information is not available.


Price Based on Earnings

Information is not available.

Information is not available.


Price Based on Expected Growth

Information is not available.


Price Based on Value of Assets

Information is not available.


Next Steps

Future Growth

How is Nxstage Medical expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

127.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Information is not available.

Information is not available.

High Growth Earnings: NXTM is forecast to remain unprofitable over the next 3 years.

Information is not available.

Information is not available.


Earnings per Share Growth Estimates


Future Return on Equity

Information is not available.


Next Steps

Past Performance

How has Nxstage Medical performed over the past 5 years?

19.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Information is not available.

Information is not available.

Information is not available.


Return on Equity

Information is not available.


Return on Assets

Information is not available.


Return on Capital Employed

Information is not available.


Next Steps

Financial Health

How is Nxstage Medical's financial position?


Financial Position Analysis

Information is not available.

Information is not available.


Debt to Equity History and Analysis

Information is not available.

Information is not available.


Balance Sheet

Information is not available.

Information is not available.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Information is not available.

Information is not available.


Next Steps

Dividend

What is Nxstage Medical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Information is not available.

Information is not available.

Stable Dividend: Insufficient data to determine if NXTM's dividends per share have been stable in the past.

Information is not available.


Current Payout to Shareholders

Information is not available.


Future Payout to Shareholders

Information is not available.


Next Steps

Management

What is the CEO of Nxstage Medical's salary, the management and board of directors tenure and is there insider trading?

6.3yrs

Average management tenure


CEO

Jeff Burbank (55yo)

20.2yrs

Tenure

US$2,900,979

Compensation

Mr. Jeffrey H. Burbank, also known as Jeff, is Founder of NxStage Kidney Care, Inc., and serves as its Chief Executive Officer. Mr. Burbank founded Nxstage Medical, Inc. in December 1998 and has been its C ...


CEO Compensation Analysis

Information is not available.

Information is not available.


Management Age and Tenure

6.3yrs

Average Tenure

55yo

Average Age

Information is not available.


Board Age and Tenure

11.8yrs

Average Tenure

67yo

Average Age

Information is not available.


Insider Trading

Information is not available.


Ownership Breakdown


Management Team

  • Matthew Towse (55yo)

    Senior VP

    • Tenure: 5.6yrs
    • Compensation: US$1.11m
  • Jeff Burbank (55yo)

    Founder

    • Tenure: 20.2yrs
    • Compensation: US$2.90m
  • Joe Turk (50yo)

    President

    • Tenure: 5.3yrs
    • Compensation: US$1.82m
  • Winifred Swan (54yo)

    Senior VP

    • Tenure: 18.3yrs
    • Compensation: US$949.81k
  • Darren Scandone (64yo)

    Senior Vice President of Human Resources

    • Tenure: 0yrs
  • Tom Shea (55yo)

    COO & Senior VP of Manufacturing Operations

    • Tenure: 0yrs
    • Compensation: US$682.03k
  • Kristen Sheppard

    Vice President of Investor Relations

    • Tenure: 10.7yrs
  • Allan Collins

    Head of Scientific Advisory Board & Chief Medical Officer

    • Tenure: 4.5yrs
  • Todd Snell (47yo)

    Senior Vice President of Quality Assurance

    • Tenure: 6.4yrs
    • Compensation: US$669.93k
  • Jeff Rains

    Senior Vice President of Sales & Marketing

    • Tenure: 6.1yrs

Board Members

  • Reid Perper (58yo)

    Independent Director

    • Tenure: 13.4yrs
    • Compensation: US$208.01k
  • Robert Funari (67yo)

    Non-Executive Chairman

    • Tenure: 5.8yrs
    • Compensation: US$265.51k
  • Craig Moore (74yo)

    Independent Director

    • Tenure: 17.1yrs
    • Compensation: US$208.01k
  • Jeff Burbank (55yo)

    Founder

    • Tenure: 20.2yrs
    • Compensation: US$2.90m
  • Earl Lewis (73yo)

    Independent Director

    • Tenure: 10.3yrs
    • Compensation: US$200.51k
  • Dan Giannini (68yo)

    Independent Director

    • Tenure: 13.3yrs
    • Compensation: US$213.01k
  • Jean Mixer (49yo)

    Director

    • Tenure: 6.3yrs
    • Compensation: US$210.51k
  • Allan Collins

    Head of Scientific Advisory Board & Chief Medical Officer

    • Tenure: 4.5yrs
  • Michael Kraus

    Member of Chronic Scientific Advisory Board

    • Tenure: 0yrs
  • Chris Chan

    Member of Chronic Scientific Advisory Board

    • Tenure: 0yrs

Company Information

NxStage Medical, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NxStage Medical, Inc.
  • Ticker: NXTM
  • Exchange: NasdaqGS
  • Founded: 1998
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$2.000b
  • Shares outstanding: 66.68m
  • Website: https://www.nxstage.com

Number of Employees


Location

  • NxStage Medical, Inc.
  • 350 Merrimack Street
  • Lawrence
  • Massachusetts
  • 1843
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
N5XDB (Deutsche Boerse AG)YesCommon SharesDEEUROct 2005
NXTMNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDOct 2005

Biography

NxStage Medical, Inc., a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/02/22 00:06
End of Day Share Price2019/02/21 00:00
Earnings2018/09/30
Annual Earnings2017/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)